Amid these developments, Tenaya announced the departure of Leone Patterson, its Chief Financial and Business Officer, and is currently seeking a replacement. Despite this, analyst firms such as H ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

Chief Executive Officer of Tenaya Therapeutics. "Funds from this grant will support our ongoing RIDGE-1 clinical trial of TN-401, a potential best-in-class gene therapy for the treatment of PKP2 ...

Tenaya is conducting the RIDGE-1 Phase 1b clinical trial of TN-401 in patients with PKP2-associated ARVC. To support TN-401’s clinical development, the company is currently enrolling the RIDGE ...